Zevra Therapeutics Inc (ZVRA) FinancialsZVRAZevra Therapeutics Inc

Evaluating the bottom line, Zevra Therapeutics, Inc. maintains a gross margin of 95.36%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 42.30%, while the net margin is 22.07%. These profitability ratios, combined with a Return on Equity (ROE) of 34.19%, provide a clear picture of how effectively ZVRA converts its operational activities into shareholder value.

In the context of the broader market, ZVRA competes directly with industry leaders such as PHAR and IRWD. With a market capitalization of $582.55M, it holds a significant position in the sector. When comparing efficiency, ZVRA's gross margin of 95.36% stands against PHAR's N/A and IRWD's 100.00%. Such benchmarking helps identify whether Zevra Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

Zevra's revenue for Q2 2026 was $39.7 million, a 53% increase year-over-year, and the gross margin was 95.36%. The company has shown a significant improvement in net income, with a reported net income of $8.4 million in Q2 2026.